Differential effects of antihypertensive treatment on the retinal microcirculation: An anglo-scandinavian cardiac outcomes trial substudy

Hypertension

Volumn 54, Issue 2, 2009, Pages 405-408

  Thom, Simon ^a,f   Stettler, Christoph ^a,b   Stanton, Alice ^b   Witt, Nicholas ^a   Tapp, Robyn ^a,d   Chaturvedi, Nish ^a   Allemann, Sabin ^c   Mayet, Jamil ^a   Sever, Peter ^a   Poulter, Neil ^a   O'Brien, Eoin ^e   Hughes, Alun ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f International Centre for Circulatory Health   (United Kingdom)

Author keywords

Amlodipine; Antihypertensive treatment; Atenolol; Hypertension; Microcirculation; Retina

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; TRIACYLGLYCEROL; ANTIHYPERTENSIVE AGENT;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERIOLE; ARTERIOLE LENGTH DIAMETER RATIO; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL PARAMETERS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTICENTER STUDY; OPHTHALMOSCOPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA BLOOD FLOW; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; MICROCIRCULATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROBABILITY; PROSPECTIVE STUDY; RETINA BLOOD VESSEL; RETINA DISEASE; RISK ASSESSMENT; SCANDINAVIA; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MICROCIRCULATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; PROSPECTIVE STUDIES; RETINAL DISEASES; RETINAL VESSELS; RISK ASSESSMENT; SCANDINAVIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 68549111153     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.133819     Document Type: Article

References (23)

1. Hughes AD, Wong TY, Witt N, Evans R, Thom SA, Klein BE, Chaturvedi N, Klein R. Determinants of retinal microvascular architecture in normal subjects. Microcirculation. 2009;16:159-166.
2. Hughes AD, Martinez-Perez E, Jabbar AS, Hassan A, Witt NW, Mistry PD, Chapman N, Stanton AV, Beevers G, Pedrinelli R, Parker KH, Thom SA. Quantification of topological changes in retinal vascular architecture in essential and malignant hypertension. J Hypertens. 2006;24:889-894.
3. Stanton AV, Wasan B, Cerutti A, Ford S, Marsh R, Sever PS, Thom SA, Hughes AD. Vascular network changes in the retina with age and hypertension. J Hypertens. 1995;13:1724-1728.
4. Hughes AD, Stanton AV, Jabbar AS, Chapman N, Martinez-Perez ME, Thom SA. Effect of antihypertensive treatment on retinal microvascular changes in hypertension. J Hypertens. 2008;26:1703-1707.
5. Dahlöf B, Stenkula S, Hansson L. Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment. Blood Press. 1992;1:35-44.
6. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366: 895-906.
7. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens. 2001;19:1139-1147.
8. Stanton S, Fitzgerald D, Hughes A, Mayet J, O'Brien E, Sever P, Shields D, Thom S. An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease. J Human Hypertens. 2001;15(S1):13-18.
9. Chapman N, Witt N, Gao X, Bharath AA, Stanton AV, Thom SA, Hughes AD. Computer algorithms for the automated measurement of retinal arteriolar diameters. Br J Ophthalmol. 2001;85:74-79.
10. Witt N, Wong TY, Hughes AD, Chaturvedi N, Klein BE, Evans R, McNamara M, Thom SA, Klein R. Abnormalities of retinal microvascular structure and risk of mortality from ischemic heart disease and stroke. Hypertension. 2006;47:975-981.
11. Schiffrin EL, Pu Q, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens. 2002;15:105-110.
12. Sare GM, Gray LJ, Bath PMW. Effect of antihypertensive agents on cerebral blood flow and flow velocity in acute ischaemic stroke: systematic review of controlled studies. J Hypertens. 2008;26:1058-1064.
13. Wikstrand J, Trimarco B, Ricciardelli B, de Luca N, Volpe M. Reversal of structural cardiovascular changes by antihypertensive treatment: functional consequences and time course of reversal as judged from clinical studies. In: Folkow B, ed. Hypertension, Pathophysiology and Clinical Implications of Early Structural Changes. Kiruna, Sweden: AB Hässle; 1983:348-370.
14. Ariff B, Zambanini A, Vamadeva S, Barratt D, Xu Y, Sever P, Stanton A, Hughes A, Thom S. Candesartan-and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke. 2006;37:2381-2384.
15. Christensen KL, Mulvany MJ. Vasodilation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens. 2001;19:1001-1006.
16. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFÉ investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) Study. Circulation. 2006;113:1213-1225.
17. Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD. Retinal arteriolar narrowing, hypertension, and subsequent risk of diabetes mellitus. Arch Intern Med. 2005;165:1060-1065.
18. Liew G, Wong TY, Mitchell P, Cheung N, Wang JJ. Retinopathy predicts coronary heart disease mortality. Heart. 2009;95:391-394.
19. Cheung N, Sharrett AR, Klein R, Criqui MH, Islam FM, Macura KJ, Cotch MF, Klein BE, Wong TY. Aortic distensibility and retinal arteriolar narrowing: the multi-ethnic study of atherosclerosis. Hypertension. 2007;50:617-622.
20. Ikram MK, de Jong FJ, Vingerling JR, Witteman JC, Hofman A, Breteler MM, de Jong PT. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci. 2004;45:2129-2134.
21. Cuspidi C, Meani S, Valerio C, Fusi V, Catini E, Sala C, Magrini F, Zanchetti A. Prevalence and correlates of advanced retinopathy in a large selected hypertensive population: the Evaluation of Target Organ Damage in Hypertension (ETODH) Study. Blood Press. 2005;14:25-31.
22. Tapp RJ, Williams C, Witt N, Chaturvedi N, Evans R, Thom SA, Hughes AD, Ness A. Impact of size at birth on the microvasculature: the Avon Longitudinal Study of Parents & Children. Pediatrics. 2007;120: e1225-e1228.
23. Mitchell P, Liew G, Rochtchina E, Wang JJ, Robaei D, Cheung N, Wong TY. Evidence of arteriolar narrowing in low-birth-weight children. Circulation. 2008;118:518-524.